V
Vistagen Therapeutics, Inc. (VTGN)
NCM – Real vaqt narxi. Valyuta: USD
0.57
-0.04 (-5.87%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.56
-0.01 (-1.41%)
Bozordan keyin: Mar 27, 2026, 7:12 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
0.57
-0.04 (-5.87%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
0.56
-0.01 (-1.41%)
Bozordan keyin: Mar 27, 2026, 7:12 PM EDT
Vistagen Therapeutics, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, nevropsixiatrik va nevrologik kasalliklar uchun davolash usullarini ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning mahsulotlar qatori Fasedienolni o'z ichiga oladi, bu tadqiq qilinayotgan feromonli burun spreyi bo'lib, ijtimoiy xavotirlik buzilishi bo'lgan kattalardagi xavotirlikni davolash uchun III bosqich klinik sinovdan o'tmoqda; va Itruvone, hidsiz sintetik tadqiq qilinayotgan neyroaktiv feromonli burun spreyi, bu katta depressiya buzilishini davolash uchun II bosqich klinik sinovdan o'tmoqda. U, shuningdek, ayollarda menopauza bilan bog'liq issiq bosishlarni, premenstrual disforik buzilishni va boshqa ayollar salomatligi kasalliklarini o'z ichiga olgan vazomotor alomatlarni davolash uchun II bosqich klinik sinovdan o'tayotgan hidsiz va ta'msiz sintetik tadqiq qilinayotgan feromonli burun spreyi PH80ni ishlab chiqadi; jismoniy charchoq va potentsial boshqa kasalliklar keltirib chiqaradigan kognitiv nuqsonlarni yaxshilash uchun II bosqich klinik sinovdan o'tayotgan tadqiq qilinayotgan feromonli burun spreyi PH15; saraton yoki yurak kasalligi kabi surunkali kasalliklar bilan bog'liq ishtaha yo'qolishini, shuningdek kaxeksiyani davolash uchun II bosqich klinik sinovdan o'tayotgan hidsiz va ta'msiz sintetik tadqiq qilinayotgan feromonli burun spreyi PH284; va depressiya va nevrologik kasalliklarni davolash uchun miyadagi N-metil-D-aspartat retseptoriga ta'sir qiluvchi og'iz orqali yuboriladigan pro-dori AV-101. Bundan tashqari, kompaniyaning klinik bosqichdagi mahsulotlari tarkibida feromonlarni o'z ichiga olgan burun ichiga yuboriladigan nomzodlar mavjud. U ko'plab xavotirlik bilan bog'liq kasalliklarni davolash uchun fasedienolni ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha AffaMed Therapeutics, Inc. bilan litsenziya va hamkorlik shartnomasiga ega. Vistagen Therapeutics, Inc. 1998 yilda tashkil etilgan va Kaliforniyaning Janubiy San-Fransisko shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Allen Easley Cato III, M.D., Ph.D. | Senior Vice President of Integrated Drug Development |
| Dr. Mark J. Ginski Ph.D. | Senior VP and Head of Chemistry, Manufacturing & Controls |
| Mr. Joshua S. Prince M.B.A. | Chief Operating Officer |
| Mr. Mark Adrian McPartland | Senior Vice President of Investor Relations |
| Mr. Nick B. Tressler M.B.A. | CFO, Principal Financial & Accounting Officer and Treasurer |
| Mr. Reid G. Adler Esq., J.D. | Chief Legal Officer |
| Mr. Shawn K. Singh J.D. | President, CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-18 | 8-K | vtgn-20260317.htm |
| 2026-03-16 | 8-K | vtgn-20260316.htm |
| 2026-03-11 | 8-K | vtgn-20260305.htm |
| 2026-01-09 | 8-K | vtgn-20260109.htm |
| 2025-12-22 | 8-K | vtgn-20251217.htm |
| 2025-12-03 | 8-K | vtgn-20251128.htm |
| 2025-11-13 | 10-Q | vtgn-20250930.htm |
| 2025-11-04 | 8-K | vtgn-20251103.htm |
| 2025-10-29 | 8-K | vtgn-20251027.htm |
| 2025-09-15 | 8-K | vtgn-20250909.htm |
| Ms. Elissa Cote | Chief Corporate Development Officer |
| Ms. Michelle Peters Wellington | Vice President of Communications |
| Ms. Trisha Fitzmaurice | Senior Vice President of Human Resources |